LMTX is a product (based on mythelene blue) in phase III for Alzheimer's disease. In phase II it was shown that it slowed down Alzheimer with 80 %. The good part of LMTX is that it also showed it cleared the misfolded alpha-synclein from PD models. I just noticed the phase I clinical trial is about to finish. This is very hopeful.

The good thing about LMTX is that if proven again effective in phase III for Alzheimer, it will be available for clinical use. At that same time the clinical phase II for PD will probably be done too and data will be available if this compounds possibly works on PD patients too. So it can be prescribed off-label already by doctors.

so many roles of the dice - must come up with double 6 sometime!